1. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality—A retrospective nationwide study 
Ulrik Madvig Mogensen, Charlotte Andersson, Emil Loldrup Fosbøl, Tina Ken Schramm, Allan Vaag, Nikolai Madrid Scheller, Christian Torp-Pedersen, Gunnar Gislason, Lars Køber 
Diabetes Research and Clinical Practice 
Volume 107, Issue 1, Pages (January 2015)
DOI: /j.diabres
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

2. Fig. 1 Flowchart. MI=myocardial infarction.
Diabetes Research and Clinical Practice  , DOI: ( /j.diabres )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

3. Fig. 2
Proportions of initial drug use (insulin secretagogoues (IS), metformin or a combination of IS and metformin at initiation of glucose lowering therapy) among included patients. There was no interaction between initial drug use and the used combination treatment (p=0.71).
Diabetes Research and Clinical Practice  , DOI: ( /j.diabres )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

4. Fig. 3
Rate Ratios (RR) and 95% confidence intervals (95% CI) for mortality (a), cardiovascular mortality (b) and a combined endpoint of cardiovascular death, myocardial infarction or stroke (c) when comparing individual insulin secretagogoues+metformin using glimepiride+metformin as reference.
Diabetes Research and Clinical Practice  , DOI: ( /j.diabres )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions